Seed · Biotech · Geneva, Switzerland · Founded 2023 · 1–9 employees
Release Therapeutics is pioneering the first cell macroencapsulation technology specifically designed to deliver therapeutic proteins beyond the blood-brain barrier for treating genetic CNS disorders. The company's proprietary technology combines an implantable macroencapsulation device with genetically modified human myoblast cells, offering a promising alternative to gene therapy. Their lead program focuses on metachromatic leukodystrophy (MLD), a devastating rare genetic disorder affecting young children, with promising preclinical results showing disease progression reversal in mouse models. The company secured CHF 3.3 million in seed funding in 2024 following successful collaboration with the Paris Brain Institute and is led by experienced CEO Thomas Mehrling with 25+ years in pharmaceutical development.
No open roles listed right now.